Introduction Gallbladder polyps are commonly detected incidentally, with a prevalence of up to 7% in adults. The vast majority are benign, while only a small fraction represent adenomas with malignant potential.
Introduction
Gallbladder polyps are commonly detected incidentally, with a prevalence of up to 7% in adults. The vast majority are benign, while only a small fraction represent adenomas with malignant potential. Because imaging cannot reliably distinguish benign from premalignant lesions, clinical guidelines have traditionally recommended surveillance or cholecystectomy based on size and risk factors. Updated European guidelines in 2022 aimed to reduce unnecessary surgery, but their real-world impact remains uncertain.
Problem Statement
Revised guidelines for gallbladder polyps have not effectively reduced unnecessary cholecystectomies for benign lesions.
Summary
The POLYP study demonstrates that despite updated 2022 European guidelines, a significant proportion of patients continue to undergo unnecessary surgery and follow-up. Among patients undergoing cholecystectomy, only 9% had true adenomas, while nearly 70% had non-neoplastic polyps, and many had no significant pathology.
Importantly, the revision of guidelines—mainly adjusting age criteria from 50 to 60 years—resulted in only a minimal reduction in surgeries. This suggests that current decision-making strategies remain insufficient to accurately identify patients who truly benefit from cholecystectomy.
Clinically, this study highlights a persistent gap between guidelines and optimal care. It underscores the need for better risk stratification tools, potentially incorporating advanced imaging, biomarkers, or predictive models, to avoid overtreatment.
The key takeaway is clear: most gallbladder polyps are benign, yet many patients still undergo unnecessary surgery—guidelines alone are not enough.
Introduction: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited improvements in survival despite the addition of immune checkpoint inhibitors to standard gemcitabine–cisplatin chemotherapy. This phase II trial evaluated ivonescimab, a novel PD-1/VEGF...
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in the management of type 2 diabetes because of their excellent glycemic, cardiovascular, and weight-loss benefits. However, concerns remain regarding their potential association with...
Introduction: Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during...
• This study evaluated 1,063 patients undergoing pancreatic surgery; 11% developed conventionally defined chyle leak. • Most clinically relevant cases were grade B, while no grade C leaks were reported. • A minimally invasive surgical...
Introduction: Endoscopic ultrasound (EUS)-guided drainage has become the preferred minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Fatty pancreas disease (FPD), also known as intrapancreatic fat deposition, has emerged as an important metabolic condition closely linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Although ectopic fat accumulation in...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.